Posted by Michael Wonder on 21 Oct 2022
Rinvoq (upadacitinib) receives its sixth US FDA approval
21 October 2022 - Rinvoq is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis.
AbbVie today announces that the US FDA has approved Rinvoq (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumour necrosis factor blocker therapy.
